Battling cancer, one genome at a time. An emerging player in the field of genomics, GenomOncology’s proprietary software and analytical tools can rapidly and interactively analyze and interpret sequenced genomic data. This approach enables GenomOncology to capture critical findings for the cancer researcher or clinical oncologist and produce a robust analysis report in less than a day.

The company expects its technology will reduce the time necessary for researchers to make new discoveries, which will ultimately provide clinicians with the information necessary to prescribe “personalized” medical treatment.

GenomOncology is a JumpStart portfolio company. The investment came from the JumpStart NEXT Fund and the JumpStart Evergreen Fund